Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psych Congress Network
How do you decide between different atypicals for a patient who’s never been on an atypical before? What about carbamazepine and oxcarbazepine for bipolar disorder? Gregory Mattingly, MD, provides practical guidance on these questions posed at the Psych Congress Regional meeting.
Psychiatry December 6th 2022
Psychiatrist.com
In a study of more than 22,000 patients with schizophrenia, schizoaffective disorder, or bipolar disorder, 24% also had obsessive-compulsive symptoms; 12% had a diagnosis of OCD. Both co-morbidities were associated with higher rates of aggressive behavior, cognitive problems, and hallucinations or delusions.
Psychiatry October 3rd 2022
Psychiatry Advisor
In this interview with Dr. Wendy Marsh, director of the Bipolar Disorders and Depression Specialty Clinics at the University of Massachusetts Chan Medical School, she discusses how treatment can better address quality-of-life issues for individuals with bipolar depression.
Psychiatry September 26th 2022
MDLinx
The association between lithium use and chronic kidney disease (CKD) has been unclear. This study showed that lithium over the long-term (i.e., 10 years) accelerated the decline in eGFR attributed to aging.
Hepatology September 26th 2022
Rakesh Jain, MD, MPH, a member of the steering committee for the Psych Congress, and co-authors Huy-Binh Nguyen, PhD, and Mousam Parikh, both of AbbVie, respond to inquiries regarding their study, which discovered a discrepancy between treatment recommendations and the prescription habits of clinicians treating bipolar disorder. The study’s motivation, the most important findings, and suggestions for doctors treating bipolar disorder who want to follow the most recent treatment recommendations are covered in Part 1 of this Q&A.
Psychiatry August 22nd 2022
The author concludes that “careful use of T3 and L-T4 can be critical mood-stabilizingoptions, especially for depressive illness that has not responded to first-line therapies,and can provide an alternative to other augmentation strategies such as atypicalantipsychotics, lithium, or esketamine/ketamine.”
Psychiatry August 16th 2022